|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US6740669||EISAI INC||Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic|| |
(10 months ago)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|EISAI INC||Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic|| |
(4 months ago)
Banzel is owned by Eisai Inc.
Banzel contains Rufinamide.
Banzel has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Banzel are:
Banzel was authorised for market use on 03 March, 2011.
Banzel is available in suspension;oral dosage forms.
The generics of Banzel are possible to be released after 14 May, 2023.
Market Authorisation Date: 03 March, 2011
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic